![Frank Verwiel](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Frank Verwiel
Vorsitzender bei
INTELLIA THERAPEUTICS, INC.
Vermögen: 649 414 $ am 31.05.2026
Profil
Frank A. G. M. Verwiel ist ein niederländischer Geschäftsmann, der bereits an der Spitze von 6 verschiedenen Unternehmen stand. Er ist Vorsitzender von ObsEva SA, Vorsitzender für Intellia Therapeutics, Inc. und Präsident von Aptalis Pharma US, Inc. Er ist auch im Vorstand von Bavarian Nordic An und Bavarian Nordic GmbH. In seiner bisherigen Laufbahn bekleidete Frank A. G. M. Verwiel die Position des VP-Hypertension & Worldwide Human Health Marketing bei Merck & Co., Inc. sowie die des President, Chief Executive Officer & Director bei Aptalis Pharma, Inc. und des President & Chief Executive Officer der Aptalis Pharma SAS, des President, Chief Executive Officer & Director bei Aptalis Holdings, Inc. sowie des Director & Director-Health Section Governing Board der Biotechnology Innovation Organization. Frank A. G. M. Verwiel erhielt einen MBA von INSEAD und einen Doktortitel von der Erasmus-Universität Rotterdam.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 09.06.2026 | 35’148 ( 0.03% ) | 494 532 $ | 31.05.2026 | |
BAVARIAN NORDIC A/S 0.01% | 31.12.2025 | 5’293 ( 0.01% ) | 154 882 $ | 31.05.2026 |
Aktive Positionen von Frank Verwiel
| Unternehmen | Position | Beginn |
|---|---|---|
| BAVARIAN NORDIC A/S | Direktor/Vorstandsmitglied | 20.04.2016 |
| INTELLIA THERAPEUTICS, INC. | Vorsitzender | 01.02.2020 |
Aptalis Pharma US, Inc.
 Aptalis Pharma US, Inc. Pharmaceuticals: MajorHealth Technology Markets pharmaceutical products for the treatment of gastrointestinal diseases and disorders | Präsident | - |
Bavarian Nordic GmbH
 Bavarian Nordic GmbH BiotechnologyHealth Technology Engages in research and development in biotechnology for cancer and infectious diseases | Direktor/Vorstandsmitglied | 01.01.2016 |
Capsida Biotherapeutics, Inc.
 Capsida Biotherapeutics, Inc. BiotechnologyHealth Technology Engages in the development of gene therapies for life threatening genetic disorders | Direktor/Vorstandsmitglied | 01.08.2019 |
Ehemalige bekannte Positionen von Frank Verwiel
| Unternehmen | Position | Ende |
|---|---|---|
| OBSEVA SA | Vorsitzender | 18.05.2022 |
| ACHILLION PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 28.01.2020 |
| AVEXIS INC | Direktor/Vorstandsmitglied | 01.06.2018 |
| INTERMUNE INC | Direktor/Vorstandsmitglied | 01.09.2014 |
| ░░░░░░░░░░░░░ ░░░░░░░░░░ ░░░░░░░░░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Frank Verwiel
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
62
Beziehungen ersten Grades
16
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 16 |
|---|---|
Merck & Co., Inc.
 Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
InterMune, Inc.
 InterMune, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that researches and develops therapies in pulmonology & orphan fibrotic diseases | Health Technology |
Achillion Pharmaceuticals, Inc.
 Achillion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes treatments for infectious diseases | Health Technology |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology advocacy organization representing biotech companies, industry leaders and state biotech associations | Commercial Services |
Aptalis Pharma LLC
 Aptalis Pharma LLC Pharmaceuticals: MajorHealth Technology Develops, manufactures, markets pharmaceutical products for cystic fibrosis and gastroenterology | Health Technology |
Aptalis Pharma US, Inc.
Aptalis Pharma US, Inc. Pharmaceuticals: MajorHealth Technology Markets pharmaceutical products for the treatment of gastrointestinal diseases and disorders | Health Technology |
Bavarian Nordic A/S
 Bavarian Nordic A/S BiotechnologyHealth Technology Engages in research, development and manufacturing travel vaccines | Health Technology |
INSEAD
 INSEAD Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Erasmus University Rotterdam
 Erasmus University Rotterdam Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
TA SASU
 TA SASU Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company which focuses on gastrointestinal diseases and cystic fibrosis | Health Technology |
Bavarian Nordic GmbH
Bavarian Nordic GmbH BiotechnologyHealth Technology Engages in research and development in biotechnology for cancer and infectious diseases | Health Technology |
Aptalis Holdings, Inc.
 Aptalis Holdings, Inc. Pharmaceuticals: MajorHealth Technology Operating as a holding company that develops, manufactures, licenses, markets and distributes therapies | Health Technology |
ObsEva SA
 ObsEva SA Pharmaceuticals: MajorHealth Technology Provides therapeutic treatments to increase women's reproductivity | Health Technology |
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Operates as a clinical-stage gene therapy company | Health Technology |
Intellia Therapeutics, Inc.
 Intellia Therapeutics, Inc. BiotechnologyHealth Technology Develops novel and potentially curative therapeutics | Health Technology |
Capsida Biotherapeutics, Inc.
Capsida Biotherapeutics, Inc. BiotechnologyHealth Technology Engages in the development of gene therapies for life threatening genetic disorders | Health Technology |
